docetaxel + ergocalciferol

Docetaxel + Vitamin D2 (ergocalciferol) is an investigational combination regimen being evaluated in Phase III clinical trials for the treatment of metastatic breast cancer, specifically in patients with vitamin D deficiency. The regimen combines docetaxel, a taxane-class chemotherapy agent that stabilizes microtubules to inhibit cell division and induce apoptosis, with ergocalciferol, a form of vitamin D that acts as an agonist for the vitamin D receptor (VDR). The VDR is a nuclear receptor that regulates genes involved in cell proliferation and differentiation, and preclinical evidence suggests that vitamin D analogues may enhance the anti-tumor activity of taxanes. The primary study (GORG-002, NCT00944424) sponsored by King Faisal Specialist Hospital & Research Center compares high-dose versus standard-dose vitamin D2 supplementation in combination with docetaxel to determine if optimizing vitamin D levels improves clinical outcomes such as progression-free survival and overall survival in this patient population.

Other names

docetaxel + vitamin d2docetaxel + vitamin ddocetaxel and ergocalciferol